← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT05560477

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

Trial Parameters

Condition Meniscus Tear
Sponsor University of Cincinnati
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 74
Sex ALL
Min Age 18 Years
Max Age 40 Years
Start Date 2023-04-26
Completion 2026-01
Interventions
AM3101Saline Placebo

Brief Summary

The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.

Eligibility Criteria

Inclusion Criteria: 1. Male or female ≥ 18 and ≤ 40 years old at time of screening. 2. MRI evidence of ACL plus meniscus tear, or isolated meniscus tear. 3. Body mass index (BMI) ≤ 40 kg/m2. 4. Liver and kidney function panels within normal ranges at time of screening 5. Willing and able to comply with the study procedures and visit schedule, and able to follow oral and written instructions. 6. Willing and able to sign an IRB approved informed consent Exclusion Criteria: 1. Have any concomitant ligament injury requiring surgical repair or reconstruction other than the ACL. 2. Have a history of previous meniscus injury that currently needs to be treated or has been treated surgically. 3. Have evidence of arthritis ≥ Grade III (Outerbridge classification) in the affected compartment or greater than Kellgren Lawrence Grade 3. 4. Elevated AST or ALT liver enzymes at time of screening 5. Pregnant or nursing mothers, or women planning on getting pregnant during the time they will be particip

Related Trials